IDNLearn.com: Where your questions meet expert answers and community support. Discover comprehensive answers to your questions from our community of experienced professionals.
An introduction of recombinant DNA technology to pharmaceutical industry did NOT allow for: a. Improved drug safety b. High level of drug modification/alteration c. Mass-production of the biopharmaceuticals d. Higher average prices of the major biopharmaceuticals e. All of the above were the consequences of the switch to recombinant DNA technology in pharmaceutical industry
Sagot :
Thank you for joining our conversation. Don't hesitate to return anytime to find answers to your questions. Let's continue sharing knowledge and experiences! IDNLearn.com is committed to providing accurate answers. Thanks for stopping by, and see you next time for more solutions.
